PuSH - Publication Server of Helmholtz Zentrum München: Is prevention of atopic eczema with hydrolyzed formulas cost-effective? A health economic evaluation from Germany.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Mertens, J.* ; Stock, S.* ; Lüngen, M.* ; von Berg, A.* ; Krämer, U.* ; Filipiak-Pittroff, B.* ; Heinrich, J. ; Koletzko, S.* ; Grubl, A.* ; Wichmann, H.-E. ; Bauer, C.-P.* ; Reinhardt, D.* ; Berdel, D.* ; Gerber, A.*

Is prevention of atopic eczema with hydrolyzed formulas cost-effective? A health economic evaluation from Germany.

Pediatr. Allergy Immunol. 23, 597-604 (2012)

DOI

PMC

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

To cite this article: Mertens J, Stock S, Lungen M, Berg AV, Kramer U, Filipiak-Pittroff B, Heinrich J, Koletzko S, Grubl A, Wichmann H-E, Bauer C-P, Reinhardt D, Berdel D, Gerber A. Is Prevention of Atopic Eczema with Hydrolyzed Formulas Cost-Effective? A Health Economic Evaluation from Germany. Pediatr Allergy Immunol 2012: 23: 597604. Abstract Objective: The German Infant Nutritional Intervention (GINI) trial, a prospective, randomized, double-blind intervention, enrolled children with a hereditary risk for atopy. When fed with certain hydrolyzed formulas for the first 4 months of life, the risk was reduced by 2645% in PP and 829% in intention-to-treat (ITT) analyses compared with children fed with regular cows milk at age 6. The objective was to assess the cost-effectiveness of feeding hydrolyzed formulas. Patients and Methods: Cost-effectiveness was assessed with a decision tree model programmed in TreeAge. Costs and effects over a 6-yr period were analyzed from the perspective of the German statutory health insurance (SHI) and a societal perspective at a 3% effective discount rate followed by sensitivity analyses. Results: The extensively hydrolyzed casein formula would be the most cost-saving strategy with savings of 478 (sic) per child treated in the ITT analysis (CI95%: 12 (sic); 852 (sic)) and 979 (sic) in the PP analysis (95%CI: 355 (sic); 1455 (sic)) from a societal perspective. If prevented cases are considered, the partially whey hydrolyzed formula is cost-saving (ITT -5404 (sic), PP -6358 (sic)). From an SHI perspective, the partially whey hydrolyzed formula is cost-effective, but may also be cost-saving depending on the scenario. An extensively hydrolyzed whey formula also included into the analysis was dominated in all analyses. Conclusions: For the prevention of AE, two formulas can be cost-effective or even cost-saving. We recommend that SHI should reimburse formula feeding or at least the difference between costs for cows milk formula and the most cost-effective formula.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

2.459

1.199